Centro Hospitalar Universitario De Santo Antonio E.P.E. — Clinical Trial Site

14 Registered trials

5 Currently recruiting

Organisation

Centro Hospitalar Universitario De Santo Antonio E.P.E.

Location

Porto, Portugal

Identifier

ORG-100047083

Address

Largo Professor Abel Salazar, 4050-011, Portugal

Departments

5801: Hematologia Clinica
Cardiology
Cardiology department
Clinical Immunology
CMIN - Infancia e Adolescencia
Dermatology
Gastrology
Medical Oncology
Nephrology
Neurology
Pediatrics Service
Serviço de Doenças Infeciosas

Clinical trials at this site (14)

Search interface

A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea… Recruiting

2022-501980-42-00 Anemia associated with Chronic Kidney Disease 5 2023-12-21
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting

2022-502281-25-00 Focal Onset Seizures 5 2023-09-27
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting

2022-502851-79-00 Active Idiopathic Inflammatory Myopathy (IIM) 5 2023-09-20
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma… Recruiting

2022-501943-34-00 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease 5 2023-06-27
Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended

2022-502238-22-00 Ulcerative Colitis 5 2024-05-14
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara) Ended

2022-503091-89-00 Delayed graft function 4 2024-02-15
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap… Ended

2022-502653-34-01 Atopic dermatitis and moderate-to severe atopic hand ec 11 2024-05-30
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arteri… Ended

2022-502378-17-00 Pulmonary Arterial Hypertension 4 2024-03-20
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended

2023-503614-80-00 Pulmonary Arterial Hypertension 5 2023-12-14
Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV … Ended

2022-503137-66-00 Human immunodeficiency virus (HIV) 5 2023-11-29
Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart… Ended

2022-502409-14-00 Heart failure with reduced ejection fraction 11 2023-08-04
A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended

2022-501353-37-00 Reversal of anticoagulation effect in patients on a FXa 5